Early and Timely Use of Hemofiltration Therapy with Poly Methyl Meth Acrylate (PMMA) Filters in Severe COVID-19 Adult Respiratory Distress Syndrome Patients: A Single Centre Study in India
Main Article Content
Abstract
A high Interleukin-6 (IL-6) level in COVID-19 plays a major role in the pathophysiology and is considered a reliable parameter in predicting the adversity of the disease. In COVID-19. Extracorporeal blood purification has been proposed as an adjuvant therapy and it aims at controlling the dysregulation in the immune system. Essentially, it lowers the upregulated levels of several mediators and therefore controls the cytokine storm, instead of actively targeting individual pathways of inflammation. Positive IL-6 balance post-Polymethyl methacrylate (PMMA) filter used for Cytokine storm in COVID-19 patients with dialysis has shown to be an independent predictor of mortality. A retrospective analysis of seventeen patients wherein hemofiltration was used for cytokine storm with dialysis, sepsis, and septic shock. The inflammatory markers post-hemofiltration sessions were supervised to understand hemofiltration's efficacy. The average age of the patients was 70.2 (18.2) years. They were classified as responders or non-responder groups based on the decrease or no change/ increase respectively between the pre-and post-filtration IL-6 levels. A 3.6-fold increase was noticed in non-responders (N=11) for IL-6 levels post hemofiltration. Responders demonstrated a 21.4% (p<0.05) reduction in IL-6 levels post hemofiltration. Of these, 4 who survived demonstrated a decrease in IL-6 levels of 66.2%. Of 10 non-responders, none survived. However, the survival rate was 71.43 percent among the responders. There was a significant statistical difference in the mortality rate between the two groups (p= 0.003).Cytokine storm, an overwhelming immunological response in COVID-19 patients, can be controlled successfully by the early and timely use of hemofiltration therapy with PMMA filters like Hemofeel. However, patients with higher positive IL-6 balance post-hemofiltration may be associated with limited outcomes.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol. 2020; 39(7): 2085-2094. doi: 10.1007/s10067-020-05190-5.
II. Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin. Exp. Immunol. 2004; 136: 95–103.
III. Quiroga B, Muñoz Ramos P, Giorgi M, de Santos A, Núñez A, Ortiz A, et al. Dynamic assessment of interleukin-6 during hemodialysis and mortality in coronavirus disease-19. Ther Apher Dial. 2021; 25(6): 908-916. doi: 10.1111/1744-9987.13626.
IV. Feng Y, Peng JY, Peng Z. Blood purification in sepsis and systemic inflammation. Curr Opin Crit Care. 2021; 27(6): 582-586.
doi: 10.1097/MCC.0000000000000890.
PMID: 34581298.
V. Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, et al. COVID-19: combining antiviral and anti- inflammatory treatments. Lancet Infect Dis. 2020; 20(4): 400–402. doi: 10.1016/S1473-3099(20)30132-8.
VI. Sarzi-Puttini P, Giorgi V, Sirotti S, Marotto D, Ardizzone S, Rizzardini G, et al. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin Exp Rheumatol. 2020; 38(2): 337–342.
VII. Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the experience of clinical immunologists from China. Clin Immunol 2020; 108393.
VIII. Nadim MK, Forni LG, Mehta RL, Connor MJ, Liu KD, Ostermann M et al. Publisher correction: COVID-19-associated acute kidney injury: consensus report of the 25(th) Acute Disease Quality Initiative (ADQI) Workgroup. Nat Rev Nephrol 2020; 16: 765.
IX. Harm S, Schildböck C, Hartmann J. Cytokine Removal in Extracorporeal Blood Purification: An in vitro Study. Blood Purif. 2020; 49(1-2): 33-43. doi: 10.1159/000502680.
X. Yang L, Liu S, Liu J, Zhang Z, Wan X, Huang B et al. COVID-19: immunopathogenesis and Immunotherapeutics. Sig Transduct Target Ther 2020; 5: 128. https://doi.org/10.1038/s41392-020-00243-2.
XI. Aziz M, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID-19: A meta-analysis. J Med Virol. 2020; 92(11):2283-2285.
doi: 10.1002/jmv.25948..
XII. Ulhaq ZS, Soraya GV. Interleukin-6 as a potential biomarker of COVID-19 progression. Med Mal Infect. 2020; 50(4): 382-383.
doi: 10.1016/j.medmal.2020.04.002.
XIII. Ferro F, Elefante E, Baldini C, Bartoloni E, Puxeddu I, Talarico R, et al. COVID-19: the new challenge for rheumatologists. Clin Exp Rheumatol. 2020; 38(2): 175–180.
XIV. McIntosh K (2020) Coronavirus disease 2019 (COVID-19). Edited by Martin S Hirsch. UpToDate, https://www.uptodate com/contents/coronavirus-disease-2019-COVID-19.
XV. Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng V et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin Infect Dis 2020; ciaa478. 10.1093/cid/ciaa478
XVI. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975.
doi: 10.1073/pnas.2005615117.
XVII. Jones G, Ding C. Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis. Clin Med Insights: Arthritis Musculoskelet Dis. 2010; 2010(3): 81–89. doi: 10.4137/CMAMD.S4864.
XVIII. Harm S, Schildböck C, Hartmann J. Cytokine Removal in Extracorporeal Blood Purification: An in vitro Study. Blood Purif. 2020; 49(1-2): 33-43. doi: 10.1159/000502680.
XIX. Kellum JA, Pike F, Yealy DM, Huang DT, Shapiro NI, Angus DC, et al. Relationship between alternative resuscitation strategies, host response and injury biomarkers, and outcome in septic shock: analysis of the protocol based care for early septic shock study. Crit Care Med. 2017; 45(3): 438–45.
XX. Banshodani M, Shintaku S, Kawanishi H. Combination therapy for COVID-19 in hemodialysis patients: Pharmacological treatments and renal replacement therapy based on the severity. Therapeutic Appheresis and Dialysis 2022; 26(2): https://doi.org/10.1111/1744-9987.13737.